Neurodegenerative disorders and nanoformulated drug development

Author： Nowacek Ari Kosloski Lisa M Gendelman Howard E

ISSN： 1743-5889

Source： Nanomedicine, Vol.4, Iss.5, 2009-07, pp. : 541-555

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neurodegenerative disorders associated with diabetes mellitus

By Ristow Michael

Journal of Molecular Medicine, Vol. 82, Iss. 8, 2004-08 ,pp. : 510-529

Springer Publishing Company

Access to resources Recommend Favorite

Development and Validation of a GC-MS Method for the Quantitation of Nanoformulated Primaquine in Whole Blood and Plasma of Mouse Model

Journal of Nanotoxicology and Nanomedicine (JNN)*, Vol. 2, Iss. 1, 2017-01 ,pp. : 44-58

IGI Global_journal

Access to resources Recommend Favorite

Targeting MicroRNAs in Prevention and Treatment of Neurodegenerative Disorders

DRUG DEVELOPMENT RESEARCH, Vol. 76, Iss. 7, 2015-11 ,pp. : 397-418

John Wiley & Sons Inc

Access to resources Recommend Favorite

Midkine and Pleiotrophin in the Treatment of Neurodegenerative Diseases and Drug Addiction

Recent Patents on CNS Drug Discovery, Vol. 10, Iss. 1, 2015-01 ,pp. : 28-33

Bentham Science Publishers

Access to resources Recommend Favorite

Drug-induced bone disorders

By Sweeney Brooke

Clinical Review in Bone and Mineral Metabolism, Vol. 3, Iss. 1, 2005-03 ,pp. : 75-92

Humana Press, Inc

Access to resources Recommend Favorite